The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
Andrew Spencer, Sung-Soo Yoon, Simon J Harrison, Shannon R Morris, Deborah A Smith, Richard A Brigandi, Jennifer Gauvin, Rakesh Kumar, Joanna B Opalinska, Christine Chen
Blood | AMER SOC HEMATOLOGY | Published : 2014
Funding for this study was provided by GlaxoSmithKline. All listed authors met the criteria for authorship set forth by the International Committee for Medical Journal Editors and retained full control of the manuscript content. Writing and editorial support, in the form of assembling tables and figures, collating author comments, copyediting, fact checking, and referencing, was done by Cactus Communications and was funded by GlaxoSmithKline.